SLAMF7 and Miyoshi myopathy: Despite the promising target for MM in many preclinical studies [59,60], anti-SLAMF7 CAR-Ts may increase the risk of infections due to the elimination of SLAMF7-expressing leukocytes, like dendritic cells and NK cells.